Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2016 16:30 ET | Source: Immunomedics

Immunomedics Engages Greenhill & Co. as Strategic Advisor

MORRIS PLAINS, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that it has engaged Greenhill & Co., Inc. (NYSE:GHL) to serve as a strategic advisor...
October 19, 2016 07:00 ET | Source: Immunomedics

Immunomedics Announces New Patents for Antibody-Drug Conjugates and Vaccines for Cancer Therapy

MORRIS PLAINS, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent 9,458,242 for additional claims under the patent family “Dosages...
October 12, 2016 09:05 ET | Source: Immunomedics

Immunomedics Announces Closing of $30 Million Financing

MORRIS PLAINS, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) announced today that it has closed on a previously disclosed underwritten offering of 10,000,000 shares of...
October 05, 2016 08:00 ET | Source: Immunomedics

Immunomedics Announces $30 Million Financing

MORRIS PLAINS, N.J., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has priced an underwritten offering of 10,000,000 shares of common stock and...
August 31, 2016 07:00 ET | Source: Immunomedics

Immunomedics to Present at Upcoming Investor Conferences

MORRIS PLAINS, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that the Company will present at three upcoming investor conferences: Credit Suisse 2016...
August 18, 2016 07:00 ET | Source: Immunomedics

Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer Cells Published

MORRIS PLAINS, N.J., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab...
August 17, 2016 16:00 ET | Source: Immunomedics

Immunomedics Announces Fiscal 2016 Results and Clinical Program Developments

MORRIS PLAINS, N.J., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today reported financial results for the fourth quarter and fiscal year ended June 30, 2016. The Company...
August 11, 2016 07:00 ET | Source: Immunomedics

Immunomedics Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2016 Financial Results

MORRIS PLAINS, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Wednesday, August 17, 2016 at...
June 28, 2016 07:00 ET | Source: Immunomedics

Immunomedics Announces New U.S. Patent for Sacituzumab Govitecan (Immu-132) Antibody-Drug Conjugate (ADC)

MORRIS PLAINS, N.J., June 28, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent 9,375,489, entitled “Antibody-SN-38 Immunoconjugates with a CL2A...
June 21, 2016 08:00 ET | Source: Immunomedics

Immunomedics Appoints Michael R. Garone as New Chief Financial Officer

MORRIS PLAINS, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the appointment of Michael R. Garone as Vice President, Finance, and Chief Financial...